An arsenic oxoacid consisting of three hydroxy groups attached to a central arsenic atom.
Chemical ID:
MESH:C032793
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK3 protein]; Acetylcysteine inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK3 protein]; Arsenic Trioxide results in decreased phosphorylation of and results in decreased activity of MAPK3 protein; Arsenic Trioxide results in increased phosphorylation of and results in increased activity of MAPK3 protein; HTS 466284 inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Phloretin inhibits the reaction [Arsenic Trioxide results in decreased expression of MAPK3 mRNA]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Arsenic Trioxide co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK3 protein]; 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK3 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK3 protein]; [acetyl-11-ketoboswellic acid co-treated with Arsenic Trioxide] results in decreased phosphorylation of MAPK3 protein; [Arsenic Trioxide co-treated with 6,7-dimethoxy-3-phenylquinoxaline] results in decreased activity of MAPK3 protein; [Arsenic Trioxide co-treated with phytosphingosine] results in decreased phosphorylation of MAPK3 protein; [Arsenic Trioxide co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of and results in increased activity of MAPK3 protein; [IL24 protein co-treated with Arsenic Trioxide] results in increased phosphorylation of MAPK3 protein; [Quercetin co-treated with Arsenic Trioxide] results in increased phosphorylation of and results in increased activity of MAPK3 protein; [Sulindac co-treated with Arsenic Trioxide] results in increased phosphorylation of MAPK3 protein; Acetylcysteine inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK3 protein]; AKT1 protein inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK3 protein]; ARL6IP5 protein promotes the reaction [Arsenic Trioxide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Arsenic Trioxide inhibits the reaction [Deoxyglucose results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Arsenic Trioxide inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]; Arsenic Trioxide inhibits the reaction [IGF1 protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Arsenic Trioxide inhibits the reaction [Indomethacin results in decreased phosphorylation of MAPK3 protein]; Arsenic Trioxide inhibits the reaction [lonidamine results in increased phosphorylation of MAPK3 protein]; Arsenic Trioxide inhibits the reaction [Sirolimus results in increased phosphorylation of MAPK3 protein]; Arsenic Trioxide inhibits the reaction [temsirolimus results in increased phosphorylation of MAPK3 protein]; Arsenic Trioxide inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK3 protein]; Arsenic Trioxide inhibits the reaction [TNF protein results in increased phosphorylation of MAPK3 protein]; Arsenic Trioxide inhibits the reaction [Tunicamycin results in decreased phosphorylation of MAPK3 protein]; Arsenic Trioxide inhibits the reaction [VEGFA protein results in increased phosphorylation of MAPK3 protein]; Arsenic Trioxide promotes the reaction [Curcumin results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Arsenic Trioxide promotes the reaction [MAPK3 protein promotes the reaction [FOS protein binds to CDKN1A promoter]]; Arsenic Trioxide promotes the reaction [Sulindac results in increased phosphorylation of MAPK3 protein]; Arsenic Trioxide promotes the reaction [Tretinoin results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Arsenic Trioxide results in increased phosphorylation of and results in increased activity of MAPK3 protein; bisindolylmaleimide I inhibits the reaction [[Arsenic Trioxide co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Indomethacin inhibits the reaction [Arsenic Trioxide results in decreased phosphorylation of MAPK3 protein]; KIRA6 inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK3 protein]; MAPK3 protein affects the reaction [Arsenic Trioxide results in increased expression of CCND1 protein]; MAPK3 protein affects the reaction [Arsenic Trioxide results in increased expression of CDC6 protein]; MAPK8 mutant form inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK3 protein]; MT2A protein inhibits the reaction [Arsenic Trioxide results in increased expression of MAPK3 protein modified form]; setanaxib inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK3 protein]; Sorafenib inhibits the reaction [Arsenic Trioxide results in increased activity of MAPK3 protein]; Sulindac promotes the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK3 protein]; temsirolimus inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [[Arsenic Trioxide co-treated with Tetradecanoylphorbol Acetate] results in increased phosphorylation of and results in increased activity of MAPK3 protein]; U 0126 inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; U 0126 inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK3 protein]; U 0126 promotes the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK3 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK3 protein]; [Arsenic Trioxide co-treated with 6,7-dimethoxy-3-phenylquinoxaline] results in decreased activity of MAPK3 protein; Acetylcysteine inhibits the reaction [Arsenic Trioxide results in decreased phosphorylation of MAPK3 protein]
